Russian Heart Failure Journal 2013year Pulse decreasing therapy and parameters of central aortic pressure in patients with chronic heart failure of ischemic etiology


To access this material please log in or register

Register Authorize
2013/№1

Pulse decreasing therapy and parameters of central aortic pressure in patients with chronic heart failure of ischemic etiology

Temirsultanova T. Kh.

Keywords: CHF, central pressure

DOI: 10.18087/rhfj.2013.1.1790

Relevance. Assessment of vascular stiffness allows diagnosis of arterial lesions at the non-clinical stage, revealing of individuals with high cardiovascular risk. It is still questionable, how parameters of central aortic pressure (CAP) change in patients with CHD complicated by CHF during pulse decreasing therapy. Objective. Compare influence of two regimens of heart rate control therapy (beta-blocker bisoprolol vs. beta-blocker bisoprolol + If -channel inhibitor ivabradine) on CAP parameters in CHF patients. Materials and methods. 50 patients with CHF, angina FC I–III against post-infarction cardiosclerosis were examined. Results. Patient groups taking bisoprolol (n=25, mean CHF FC – 2.6±0.1, LVEF – 30.8±1.4 %) and combination of bisoprolol and ivabradine (n=25, CHF FC – 2.4±0.2, LVEF – 28.7±1.7 %) were compared. Results. Due to the therapy carried out, in Group 1, mean CHF FC went down to 2.2±0.1 in 3 months of treatment (15.6 %; р<0.001). In Group 2 mean CHF FC in 3 months of therapy went down to 2.1±0.2 (12.5 %; р<0.003). In 3 months, highly significant improvement of LV systolic function was observed in both groups: LVEF in Group 1 increased by 10.1 % from the baseline level and reached 33.7±1.2 % (р<0.005); in Group 2, LVEF increased to 33.8±2.1 % (15.1 %; р<0.0001). In group 2, appropriately greater pulse decrease was observed in 3 months of treatment, in comparison with Group 2. In bisoprolol group, CAP increased to 119.1±2.4 mm Hg, augmentation pressure (АР, mm Hg) increased from 9.9 [3.1;1 4.1] to 14.1 mm Hg [10.1; 17.1] in 3 months of therapy (р=0.05). In Group 2, dynamics of these parameters was analogous. Augmentation index (AIx, %) in Group 1 was 25.9 % [9.9; 30.9] at baseline and 33.5 % [24.7; 38.7] in 3 months of therapy (р<0.04). Similar situation was observed in Group 2. Buckberg index (SEVR,%) in Group 1 was at the average 165.1±5.7 % at the baseline, and 183.5±4.3 % in 3 months of treatment (р<0.0001). In Group 2, it was 178.1±6.1 %, in 3 months – 199.1±6.7 % (р<0.0001). Conclusion. Comparison of two regimens of heart rate control therapy in CHF patients showed not only greater decrease of pulse against the combination therapy, but also significantly more marked improvement of LV systolic function.
  1. Nishijima T, Nakayama Y, Tsumura K et al. Pulsatility of ascending aortic blood pressure waveform is associated with an increased risk of coronary heart disease. Am J Hypertens. 2001;14 (5 Pt 1):469–473.
  2. Safar ME, Blacher J, Pannier B et al. Central pulse pressure and mortality in end-stage renal disease. Hypertension. 2002;39 (3):735–738.
  3. Nurnberger J, Keflioglu-Scheiber A, Opazo Saez AM. Augmentation index is associated with cardiovascular risk. J Hypertens. 2002;20 (12):2407–2414.
  4. Dahlof B, Sever PS, Poulter NR et al.; for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366 (9489):895–906.
  5. Williams B, Lacy PS, Thorn SM et al. Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113 (9):1213–1225.
  6. Профилактика, диагностика и лечение артериальной гипертензии. Рекомендации РМОГ и ВНОК (четвертый пересмотр). Приложение к журналу «Кардиоваскулярная терапия и профилактика». 2010. – 50с.
  7. Roman MJ, Devereux RB, Kizer JR et al. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension. 2007;50 (1):197–203.
  8. Sharman JE. New insights into cardiovascular risk from the exercise central waveform. 2008;2 (4):132–137.
  9. Laurent S, Boutouyrie P, Asmar R et all. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension. 2001;37 (5):1236–1241.
  10. Agabiti-Rosei E, Mancia G, O'Rourke MF et al. Central blood pressure measurements and antihypertensive therapy: a consensus do­cument. Hypertension. 2007;50 (1):154–160.
  11. Weber T, Auer J, O’Rourke MF et al. Increased arterial wave reflections predict severe cardiovascular events in patients undergoing percutaneous coronary interventions. Eur Heart J. 2005;26 (24):2657–2663.
  12. Nakayama Y, Tsumura K, Yamashita N et al. Pulsatility of ascen­ding aortic pressure waveform is a powerful predictor of restenosis after percutaneous transluminal coronary angioplasty. Circulation. 2000;101 (5):470–472.
  13. Hlimonenko I, Meigas K, Viigimaa M, Temitski K. Augmentation index in different severity coronary heart disease patients. IFMBE Proceedings. 2008;20 (4):242–244.
  14. Беленков Ю. Н., Васюк Ю. А., Галявич А. С. и др. Национальные Рекомендации ВНОК И ОССН по диагностике и лечению ХСН (третий пересмотр). Утверждены конференцией ОССН 15 декабря 2009 года. Журнал Сердечная недостаточность. 2010;11 (1):4–62.
Temirsultanova T. Kh. Pulse decreasing therapy and parameters of central aortic pressure in patients with chronic heart failure of ischemic etiology. Russian Heart Failure Journal. 2013;14 (1):47-52

To access this material please log in or register

Register Authorize
Ru En